Literature DB >> 26070933

High Rab27A expression indicates favorable prognosis in CRC.

Chuanbing Shi1, Xiaojun Yang2, Yijiang Ni3, Ning Hou4, Li Xu4, Feng Zhan5, Huijun Zhu6, Lin Xiong7,8, Pingsheng Chen9.   

Abstract

BACKGROUND: Rab27A is a peculiar member in Rab family and has been suggested to play essential roles in the development of human cancers. However, the association between Rab27A expression and clinicopathological characteristics of colorectal cancer (CRC) has not been elucidated yet.
METHODS: One-step quantitative real-time polymerase chain reaction (qPCR) test with 18 fresh-frozen CRC samples and immunohistochemistry (IHC) analysis in 112 CRC cases were executed to evaluate the relationship between Rab27A expression and the clinicopathological features of CRC. Cox regression and Kaplan-Meier survival analyses were performed to identify the prognostic factors for 112 CRC patients.
RESULTS: The results specified that the expression levels of Rab27A mRNA and protein were significantly higher in CRC tissues than that in matched non-cancerous tissues, in both qPCR test (p = 0.029) and IHC analysis (p = 0.020). The IHC data indicated that the Rab27A protein expression in CRC was statistically correlated with lymph node metastasis (p = 0.022) and TNM stage (p = 0.026). Cox multi-factor analysis and Kaplan-Meier method suggested Rab27A protein expression (p = 0.012) and tumor differentiation (p = 0.004) were significantly associated with the overall survival of CRC patients.
CONCLUSION: The data indicated the differentiate expression of Rab27A in CRC tissues and matched non-cancerous tissues. Rab27A may be used as a valuable prognostic biomarker for CRC patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26070933      PMCID: PMC4465473          DOI: 10.1186/s13000-015-0303-3

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


Background

Colorectal cancer (CRC) is the third most common cancer and more than 1 million people develop CRC annually [1]. It is reported that there are estimated 140,000 newly diagnosed cases of CRC and approximately 50,000 cancer deaths from CRC in America in 2013 [2, 3]. Of patients with primary CRC, nearly 20 % encounter distant metastasis at the time of diagnosis and only 10-30 % of patients with distant metastasis can have potentially curative resection of the primary tumor and the distant focus [4-6]. For CRC prognosis, survival is critically related to stage at diagnosis, with five-year survival rates of 90 % for localized cases, while 67 % for regional cases and only 10 % for distant metastatic cases [7]. Although the great developments for diagnosis and treatment for CRC, the overall survival rate of CRC patients rarely shows the encouraging result and post-operative recurrence and metastasis remain the two most challenging obstacles [8]. Hence it is valuable and necessary to identify molecular predictive markers for the prognosis, which would facilitate the selection of therapeutic strategies and further ameliorate patients’ survival for CRC [9]. The Rab family is a group of Ras-like small GTPases which locates in specific subcellular organelle and plays an important role in cell secretion, endocytosis, signal transduction, and development [10-12]. Rab27A is a peculiar member in Rab family for its specific role in human hereditary disease and dysfunction, such as Griscelli syndrome [13, 14]. Recently, several studies reported the diverse function of Rab27A in many kinds of human cancers. Differential expression of Rab27A was detected in murine xenografts of breast cancer (BC) metastasis and Rab27A was highly associated with the invasive and metastatic potential of human BC cells [15]. Rab27A enhanced various ability of glioma cell, such as developing proliferation, promoting invasion and inhibiting apoptosis [16]. Rab27A also affected exosome secretion, modified tumor microenvironment and finally promoted tumor progression [17]. Moreover, two studies reported the prognostic role of Rab27A that high Rab27A expression indicated poor survival of patients with gliomas and hepatocellular carcinoma (HCC) [18, 19]. All the above information suggest the significant relationship between Rab27A and cancer while the performance of Rab27A in CRC has yet to be explored. What function does Rab27A play in CRC deveolopment and what is the relationship between Rab27A expression and clinical features of CRC? We conducted this present research. In this retrospective study, the mRNA and protein expression of Rab27A in CRC was investigated by one-step quantitative real-time polymerase chain reaction (qPCR) test and immunohistochemistry (IHC) analysis respectively. Subsequently, the correlations of Rab27A expression with the clinicopathological parameters of CRC were further explored. Finally, the survival analysis for identifying prognostic factors was executed.

Methods

Ethics statement

The Ethics Committee of the Affiliated Hospital of Nantong University and each local hospital approved the study protocol. A written informed consent and related pictures were also acquired from each patient for publication of this present research.

CRC patient specimens

Formalin-fixed, paraffin-embedded tumor samples from 112 CRC cases and 113 matched non-cancerous tissue specimens were collected in CRC patients from the Department of Pathology, the Affiliated Hospital of Nantong University from 2003 to 2008. Representative and important clinical information were collected from hospital medical records, including gender, age, tumor size, tumor location, histological type, tumor differentiation, serum carcino-embryonic antigen (CEA) level, primary tumor (T), lymph node metastasis (N), distant metastasis (M), as well as TNM stage which was classified using the 7th American Joint Committee on Cancer (AJCC) staging system for CRC and overall survival status [20]. None of the patients received radiotherapy, chemotherapy, or immunotherapy prior to enterectomy.

One-step qPCR analysis

18 fresh CRC cancer tissue samples and 18 normal tumor-adjacent tissue samples were collected from the Department of Pathology, Affiliated Cancer Hospital of Nanjing Medical University for qPCR analysis. Total RNA extraction, quality control, and one-step qPCR analysis were performed as previously described [21, 22]. The primers for Rab27A were as follows: forward primer 5’- GTA AGT GAC ATA GTA GTT -3’ and reverse primer 5’- TTA TTC GTA GGT CTA ATG -3’. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA level was employed to standardize the measurements of the target gene and the primers for GAPDH were as follows: forward primer 5’-TGC ACC ACC AAC TGC TTA GC-3’ and reverse primer 3’-GGC ATG GAC TGT GGT CAT GAG-5’. Amplification conditions consisted of 30 min at 42 °C for reverse transcription and 2 min at 94 °C for Taq activation, followed by 35 cycles at 95 °C for 20 s, 56 °C for 20 s, and elongation at 72 °C for 30 s. Each measurement was performed in triplicate.

Tissue microarrays (TMA) construction and IHC analysis

112 CRC and 113 normal tumor-adjacent tissues were enrolled in this present study. TMA was produced by the Department of Pathology, the Affiliated Hospital of Nantong University. Core tissue biopsies (2 mm in diameter) were taken from individual paraffin-embedded sections and arranged in the new recipient paraffin blocks. TMA was cut into 4-μm sections and placed on super frost charged glass microscope slides. IHC analysis was performed as previously described [23-25]. Deparaffinized sections (4 μm thick) from array blocks were separately stained on an Autostainer Universal Staining System (LabVision, Kalamazoo, MI, USA) using mouse anti-Rab27A antibody (1:100, Abcam, Cambridge, UK). The secondary antibody used was horseradish peroxidase-conjugated antibody (Dako Cytomation, Carpinteria, CA, USA). Rab27A immunostaining observation and evaluation were simultaneously performed by two independent pathologists. IHC results were analyzed according to a previously described method [24, 26, 27]. Staining intensity was scored as follows: 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The percentage of Rab27A-positive cells was also classified into 4 categories, where 1 was given for 0-10 %, 2 for 11-50 %, 3 for 51-80 %, and 4 for 81-100 %. The product of the intensity and percentage scores gave rise to the final Rab27A staining score. The degree of Rab27A staining was sorted by a two-level grading system, and staining scores were described as follows: a score below 4 (<4) suggested low or no expression of Rab27A, while a score above 4 (≥4) suggested high expression of Rab27A.

Statistical analysis

The Rab27A mRNA expression normalized to GAPDH in CRC samples compared with matching non-cancerous tissue samples was analyzed with the Wilcoxon non-parametric signed-rank test. The relationships between Rab27A expression and clinicopathologic itemss of CRC were evaluated with χ2 tests. Survival curves were performed with Kaplan-Meier method. Univariate and multivariate Cox regression model were performed to detect the prognostic elements. For all tests, the significance level for statistical analysis was set at p < 0.05. All data were analyzed using STATA Version 12.0 ((Stata Corporation, College Station, TX, USA).

Results

Summarization of clinical data of 112 CRC patients

A total of 112 CRC cases were collected from 73 men and 39 women and the representative clinical data are summarized in Table 1. The mean age of all cases at the time of surgery was 65.14 years. There were 47 cases with tumor diameter ≥5 cm, 62 with tumor diameter <5 cm. The tumor locations of 57 patients were in colon, 51 patients in rectum and 4 patients in ileocecal junction. The histological type of tumor in 102 cases was adenocarcinoma, while the other 10 cases were identified as non-adenocarcinoma type. 1 patient encountered a well-differentiated tumor, 92 suffered moderate tumor differentiation, and 15 had poor tumor differentiation. High serum CEA level (≥15 ng/ml) was observed in 14 cases, whereas low serum CEA level (<15 ng/ml) was displayed in 71 cases. The number of patients with T1, T2, T3 were 7, 26 and 79 respectively. Positive lymph node metastasis was observed in 44 patients while distant metastasis was noticed in 5 patients. According to TNM staging system, 29 patients were in stages I, 36 patients were in stages II, 42 patients were in stages III, whereas the remaining 5 patients were in stages IV.
Table 1

Correlation of Rab27A expression with clinicopathological characteristics of 112 CRC patients

GroupsNo.Rab27Aχ2 p value
+%
Gender1.18350.277
 Male733953.4
 Female392564.1
Age (years)0.01330.908
 ≥60744256.8
 <60382257.9
Tumor size (cm)0.45850.498
 ≥5472553.2
 <5623759.7
 Insufficient data32
Tumor location1.98700.370
 Colon573256.1
 Rectum513160.8
 Ileocecal junction41
Histological type2.34250.126
 Adenocarcinoma1025654.9
 Non-adenocarcinoma10880.0
Tumor differentiation3.36340.186
 Well100.0
 Moderately925559.8
 Poorly15640.0
 Insufficient data43
Serum CEA level (ng/ml)0.28550.593
 ≥1514750.0
 <15714157.7
 Insufficient data2716
T (Primary tumor)3.04900.218
 T17685.7
 T2261661.5
 T3794253.2
N (Lymph node metastasis)5.24380.022*
 Positive443170.5
 Negative683348.5
M (Distant metastasis)0.62800.428
 Positive5240.0
 Negative1076257.9
TNM stage9.28550.026*
 Stage I291862.1
 Stage II361438.9
 Stage III423071.4
 Stage IV5240.0

*p < 0.05

Correlation of Rab27A expression with clinicopathological characteristics of 112 CRC patients *p < 0.05

Detection of Rab27A mRNA expression by qPCR test

Total RNA was extracted from 18 CRC tissues as well as matched tumor adjacent tissues, and then subjected to one-step qPCR to detect Rab27A mRNA expression. When normalizing to GAPDH, the means of Rab27A mRNA in CRC tissues and that of the corresponding non-cancerous tissues were calculated as 3.32 ± 0.518 and 1.76 ± 0.444, respectively (t = 2.281, p = 0.029). Rab27A expression in the CRC samples was nearly 1.89-fold higher than that in matched non-cancerous tissues (Fig. 1).
Fig. 1

One-step quantitative real-time polymerase chain reaction (qPCR) was employed to evaluate Rab27A mRNA expression levels in 18 colorectal cancer (CRC) tissues compared with matched non-cancerous tissues. When normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels, the Rab27A mRNA level in CRC tissues (3.32 ± 0.518) is significantly higher than that in corresponding non-cancerous tissues (1.76 ± 0.444)

One-step quantitative real-time polymerase chain reaction (qPCR) was employed to evaluate Rab27A mRNA expression levels in 18 colorectal cancer (CRC) tissues compared with matched non-cancerous tissues. When normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels, the Rab27A mRNA level in CRC tissues (3.32 ± 0.518) is significantly higher than that in corresponding non-cancerous tissues (1.76 ± 0.444)

Detection of Rab27A protein expression by IHC

High Rab27A expression was observed in 64 (57.1 %) of the 112 CRC samples compared with 47 (41.6 %) of 113 matched normal tumor-adjacent tissue samples. The difference was of statistically significance (χ2 = 5.44, p = 0.020) according to the χ2 test analysis and the data was agreeable with the previous qPCR test in which high level of Rab27A mRNA expression was detected. As is shown in Fig. 2, positive IHC staining was mainly localized in the cytoplasm and nucleus of CRC cells.
Fig. 2

Representative images of Rab27A protein expression in colorectal cancer (CRC) tissues and corresponding non-cancerous tissues with tissue microarray (TMA) by immunohistochemistry (IHC) analysis. A1, A2 and A3 High IHC staining of Rab27A protein in cytoplasm of CRC cells. B1, B2 and B3 High IHC staining of Rab27A protein in nucleus of CRC cells. C1, C2 and C3 No IHC staining of Rab27A protein in CRC cells. D1, D2 and D3 High IHC staining of Rab27A protein in non-cancerous cells. E1, E2 and E3 No IHC staining of Rab27A protein in non-cancerous cells. Original magnification × 40 in A1, B1, C1, D1 and E1; ×200 in A2, B2, C2, D2 and E2; ×400 in A3, B3, C3, D3 and E3

Representative images of Rab27A protein expression in colorectal cancer (CRC) tissues and corresponding non-cancerous tissues with tissue microarray (TMA) by immunohistochemistry (IHC) analysis. A1, A2 and A3 High IHC staining of Rab27A protein in cytoplasm of CRC cells. B1, B2 and B3 High IHC staining of Rab27A protein in nucleus of CRC cells. C1, C2 and C3 No IHC staining of Rab27A protein in CRC cells. D1, D2 and D3 High IHC staining of Rab27A protein in non-cancerous cells. E1, E2 and E3 No IHC staining of Rab27A protein in non-cancerous cells. Original magnification × 40 in A1, B1, C1, D1 and E1; ×200 in A2, B2, C2, D2 and E2; ×400 in A3, B3, C3, D3 and E3

Association between Rab27A protein expression and clinicopathological items

The association between high Rab27A protein expression and representative clinicopathological items was summarized in Table 1. High Rab27A protein expression was statistically related to N (p = 0.022) and TNM stage (p = 0.026). Relatively, other clinical items, such as gender, age, tumor size and location, histological type and tumor differentiation, serum CEA level and N, were rarely correlated with high Rab27A protein expression (Table 1).

Survival analysis

According to univariate analysis, several factors were correlated with overall survival of 112 CRC patients, including Rab27A protein expression (p = 0.001), tumor differentiation (p = 0.001), serum CEA level (p = 0.006), T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003). Moreover, multivariate analysis was executed and the results showed that Rab27A protein expression (p = 0.012) and tumor differentiation (p = 0.004) were two independent predictors of overall survival (Table 2). Kaplan-Meier survival curves in Fig. 3 further demonstrated that CRC patients with high Rab27A protein expression and well-moderately tumor differentiation encountered significantly favorable survival time.
Table 2

Univariate and multivariate analysis of prognostic factors in 112 CRC patients for overall survival

Univariate analysisMultivariate analysis
HR p value95 % CIHR p value95 % CI
Rab27A protein expression
High versus Low or no0.330.001*0.181–0.6160.360.012*0.159–0.794
Gender
Male versus Female1.430.2770.750–2.726
Age (years)
≥60 versus <601.160.6420.618–2.184
Tumor size (cm)
≥5 versus <51.210.5370.659–2.224
Tumor location
Colon versus Rectum versus Ileocecal junction1.490.1310.888–2.495
Histological type
Adenocarcinoma versus Non-adenocarcinoma2.400.2270.581–9.903
Tumor differentiation
Well-Moderately versus Poorly0.230.001*0.117–0.4490.300.004*0.134–0.689
Serum CEA level (ng/ml)
≥15 versus <152.830.006*1.356–5.8941.640.2280.735–3.639
T (Primary tumor)
T1 versus T2 versus T30.310.004*0.140–0.6920.700.5660.201–2.406
N (Lymph node metastasis)
Positive versus Negative1.410.2570.780–2.533
M (Distant metastasis)
Positive versus Negative4.350.005*1.542–12.1712.530.2810.467–13.772
TNM stage
Stage I versus Stage II versus Stage III versus Stage IV0.580.003*0.403–0.8290.680.2810.333–1.375

*p < 0.05

Fig. 3

Survival analysis of 112 colorectal cancer (CRC) patients by Kaplan-Meier method. a Overall survival rate in patients with high Rab27A protein expression (green line) was significantly higher than that in patients with low or no Rab27A expression (red line). b Overall survival rate in patients with well-moderately differentiation of tumor (green line) was significantly higher than that in patients with poorly differentiation of tumor (red line)

Univariate and multivariate analysis of prognostic factors in 112 CRC patients for overall survival *p < 0.05 Survival analysis of 112 colorectal cancer (CRC) patients by Kaplan-Meier method. a Overall survival rate in patients with high Rab27A protein expression (green line) was significantly higher than that in patients with low or no Rab27A expression (red line). b Overall survival rate in patients with well-moderately differentiation of tumor (green line) was significantly higher than that in patients with poorly differentiation of tumor (red line)

Discussion

Recently, the roles of several members of the Rab family in human cancer have drawn great attention, including Rab23 and Rab25 [28-30]. As for Rab27A, high expression of Rab27A promoted invasiveness and metastasis of breast cancer cells by secretion of insulin-like growth factor-II [14]. Rab27A modulated the tumor microenvironment and facilitated tumor development by regulating exocytosis of multivesicular endosomes and lead to exosome secretion [17]. For glioma, Rab27A acted as an oncogenic factor and significantly associated with tumor progression and poor prognosis in all grades of gliomas [18]. Similarly, in HCC, Rab27A expression was closely correlated with HCC progression and can be used as a valuable prognostic indicator for HCC patients [19]. Hence it is rationale to presume that Rab27A also performs in CRC and there are certain relationships between Rab27A expression and certain clinical features of CRC patients. The results of qPCR test with small samples of CRC showed that Rab27A expression in CRC samples was statistically increased than that in non-cancerous tissues. In the subsequent IHC analysis, the results were consistent with the previous qPCR test and the protein expression of Rab27A in CRC TMA was also higher than that in non-cancerous tissues. The data of differential expression of Rab27A in CRC in this present study was consistent with the content of previous reports which stated that expression of Rab27A was significant higher in glioma and HCC [18, 19]. In addition, high Rab27A protein expression do correlated with certain substantial clinical attributes, including N and TNM stage. The above data agreed with previous researches and supported the promotive function of Rab27A in tumorigenesis [16, 18, 19]. In the survival analyses of our present study, univariate analysis revealed that several substantial items correlated with overall survival of 112 CRC patients. Multivariate analysis further elucidated that Rab27A protein expression and tumor differentiation may identified as two independent prognostic factors for CRC prognosis in this present study. Thoroughly, Kaplan-Meier curve indicated that CRC patients with high Rab27A expression had a significantly better prognosis than that of patients with low or no expression. The data of survival analysis were in line with the previous study, which mentioned the prognostic effect of Rab27A in GC and CRC (without providing the exact survival data) [19]. So far, there are still some inconsistencies even contradictories concerning the effects of Rab27A in human cancers. Hendrix et al. reported no expression of Rab27A was detected in breast cancer [31] while Dong et al. reported that Rab27A expression was higher in primary HCC than in matched adjacent tissue [19]. High expression of Rab27A showed poor survival in gliomas and HCC as well as suggested favorable survival in GC and CRC simultaneously [18, 19]. In my view, these discrepant findings indicate that Rab27A may have different molecular mechanisms in different human cancer under specific circumstances. For instance, the secretion of exosome critically needs the present of Rab27A and the functions of tumor exosomes were dual. For one thing, exosomes could transfer tumor antigens to dendritic cells for presentation of these antigens to T lymphocytes [32]. For another, exosomes showed inhibitory functions on effector immune responses as well as promoted metastasis [33, 34]. The multiple activities of exosome may explain the complicated function of Rab27A in human cancer. Further researches that enroll larger cancer samples and elucidate the potential mechanisms of Rab27A performance are of great importance to prove our presumption. In summary, to our best knowledge, this study was the first to report on the differential expression of Rab27A in CRC and our data indicated that Rab27A may be identified as a prognostic biomarker in CRC patients.

Conclusions

In conclusion, this is the first report of the differential expression of Rab27A in CRC. High Rab27A expression was detected in CRC tissues, and that CRC patients with elevated Rab27A expression were prone to suffer malignant behaviors including positive N and advanced TNM stage. Moreover, high expression of Rab27A suggested favorable prognosis in CRC patients.
  34 in total

Review 1.  Role of Rab GTPases in membrane traffic and cell physiology.

Authors:  Alex H Hutagalung; Peter J Novick
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

2.  Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study.

Authors:  Mehdi Karoui; Françoise Roudot-Thoraval; Farida Mesli; Emmanuel Mitry; Thomas Aparicio; Gaetan Des Guetz; Gaetan DesGuetz; Christophe Louvet; Bruno Landi; Emmanuel Tiret; Iradj Sobhani
Journal:  Dis Colon Rectum       Date:  2011-08       Impact factor: 4.585

3.  Changing management and survival in patients with stage IV colorectal cancer.

Authors:  Cameron Platell; Siobhan Ng; Austin O'bichere; Niall Tebbutt
Journal:  Dis Colon Rectum       Date:  2011-02       Impact factor: 4.585

Review 4.  Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor
Journal:  Semin Immunopathol       Date:  2011-06-19       Impact factor: 9.623

5.  Upregulated ZO-1 correlates with favorable survival of gastrointestinal stromal tumor.

Authors:  Huijun Zhu; Juying Lu; Xudong Wang; Huilin Zhang; Xiaojun Tang; Jin Zhu; Yuan Mao
Journal:  Med Oncol       Date:  2013-07-03       Impact factor: 3.064

6.  Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma.

Authors:  Wei-Wei Dong; Quan Mou; Jian Chen; Jian-Tao Cui; Wen-Mei Li; Wen-Hua Xiao
Journal:  World J Gastroenterol       Date:  2012-04-21       Impact factor: 5.742

7.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

8.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Authors:  Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

9.  Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression.

Authors:  Angélique Bobrie; Sophie Krumeich; Fabien Reyal; Chiara Recchi; Luis F Moita; Miguel C Seabra; Matias Ostrowski; Clotilde Théry
Journal:  Cancer Res       Date:  2012-08-03       Impact factor: 12.701

10.  LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL).

Authors:  Yuan Mao; Da-Wei Zhang; Huijun Zhu; Hong Lin; Lin Xiong; Qing Cao; Ying Liu; Qing-Dong Li; Jia-Ren Xu; Lin-Feng Xu; Ren-Jie Chen
Journal:  Diagn Pathol       Date:  2012-12-13       Impact factor: 2.644

View more
  14 in total

1.  Prognostic Significance of Rab27A and Rab27B Expression in Esophageal Squamous Cell Cancer.

Authors:  Fengqiang Yu; Weihan Wu; Mingqiang Liang; Yu Huang; Chun Chen
Journal:  Cancer Manag Res       Date:  2020-07-27       Impact factor: 3.989

2.  The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.

Authors:  Yuan Mao; Xiaoying Wang; Feng Zheng; Changjun Wang; Qi Tang; Xiaojun Tang; Ning Xu; Huiling Zhang; Dawei Zhang; Lin Xiong; Jie Liang; Jin Zhu
Journal:  Oncotarget       Date:  2016-04-26

3.  SESN2 correlates with advantageous prognosis in hepatocellular carcinoma.

Authors:  Shaosen Chen; Weigang Yan; Weiya Lang; Jing Yu; Li Xu; Xinyu Xu; Yunlong Liu; Hongguang Bao
Journal:  Diagn Pathol       Date:  2017-01-24       Impact factor: 2.644

4.  Rab27A overexpression promotes bladder cancer proliferation and chemoresistance through regulation of NF-κB signaling.

Authors:  Jia Liu; Xue Gong; Xingwang Zhu; Dongwei Xue; Yili Liu; Ping Wang
Journal:  Oncotarget       Date:  2017-09-08

5.  Downregulation of Rab27A contributes to metformin-induced suppression of breast cancer stem cells.

Authors:  Feixue Feng; Jianping Zhang; Xiaoxuan Fan; Fang Yuan; Yinghao Jiang; Ruihua Lv; Yanxia Ma
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

Review 6.  Autophagy and Extracellular Vesicles, Connected to rabGTPase Family, Support Aggressiveness in Cancer Stem Cells.

Authors:  Aude Brunel; Gaëlle Bégaud; Clément Auger; Stéphanie Durand; Serge Battu; Barbara Bessette; Mireille Verdier
Journal:  Cells       Date:  2021-05-27       Impact factor: 6.600

7.  Effects of silencing Rab27a gene on biological characteristics and chemosensitivity of non-small cell lung cancer.

Authors:  Xia Li; Haiying Wang; Qinggan Ni; Zhiyuan Tang; Jun Ni; Liqin Xu; Hua Huang; Songshi Ni; Jian Feng
Journal:  Oncotarget       Date:  2017-10-10

8.  Prognostic significance of Rab27 expression in solid cancer: a systematic review and meta-analysis.

Authors:  Hyun Min Koh; Bo Gun Jang; Dong Chul Kim
Journal:  Sci Rep       Date:  2020-08-24       Impact factor: 4.379

9.  Specific Soft-Tissue Invasion and LMP1 Expression Are Potential Indicators of Extranodal NK/T Cell Lymphoma, Nasal Type.

Authors:  Min Jiang; Haoyue Lu; Chao Lu; Xingdong Geng; Yingjun Jia; Peng Wang; Wei Qian; Hao Huang; Xiuhong Shan
Journal:  Med Sci Monit       Date:  2018-10-25

10.  Prognostic role of Rab27A and Rab27B expression in patients with non-small cell lung carcinoma.

Authors:  Hyun Min Koh; Dae Hyun Song
Journal:  Thorac Cancer       Date:  2018-11-27       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.